|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SOCS3 |
Gene summary for SOCS3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SOCS3 | Gene ID | 9021 |
| Gene name | suppressor of cytokine signaling 3 | |
| Gene Alias | ATOD4 | |
| Cytomap | 17q25.3 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | O14543 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9021 | SOCS3 | AEH-subject3 | Human | Endometrium | AEH | 1.08e-08 | -4.67e-01 | -0.2576 |
| 9021 | SOCS3 | AEH-subject5 | Human | Endometrium | AEH | 4.06e-20 | -5.82e-01 | -0.2953 |
| 9021 | SOCS3 | EEC-subject1 | Human | Endometrium | EEC | 1.20e-11 | -4.69e-01 | -0.2682 |
| 9021 | SOCS3 | EEC-subject2 | Human | Endometrium | EEC | 1.61e-05 | -3.53e-01 | -0.2607 |
| 9021 | SOCS3 | EEC-subject3 | Human | Endometrium | EEC | 8.19e-11 | -2.36e-01 | -0.2525 |
| 9021 | SOCS3 | EEC-subject4 | Human | Endometrium | EEC | 4.03e-02 | -2.79e-01 | -0.2571 |
| 9021 | SOCS3 | EEC-subject5 | Human | Endometrium | EEC | 3.66e-16 | -5.33e-01 | -0.249 |
| 9021 | SOCS3 | GSM5276934 | Human | Endometrium | EEC | 3.49e-05 | -3.76e-01 | -0.0913 |
| 9021 | SOCS3 | GSM5276935 | Human | Endometrium | EEC | 1.70e-16 | -5.70e-01 | -0.123 |
| 9021 | SOCS3 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 2.35e-09 | -3.70e-01 | -0.1869 |
| 9021 | SOCS3 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 4.22e-15 | -5.28e-01 | -0.1875 |
| 9021 | SOCS3 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 1.82e-14 | -4.89e-01 | -0.1883 |
| 9021 | SOCS3 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 1.50e-12 | -3.78e-01 | -0.1934 |
| 9021 | SOCS3 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 5.63e-15 | -2.74e-01 | -0.1917 |
| 9021 | SOCS3 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 2.96e-16 | -2.31e-01 | -0.1916 |
| 9021 | SOCS3 | LZE4T | Human | Esophagus | ESCC | 1.94e-05 | -4.36e-01 | 0.0811 |
| 9021 | SOCS3 | LZE7T | Human | Esophagus | ESCC | 1.83e-02 | -8.49e-02 | 0.0667 |
| 9021 | SOCS3 | LZE24T | Human | Esophagus | ESCC | 7.21e-23 | 2.27e+00 | 0.0596 |
| 9021 | SOCS3 | LZE21T | Human | Esophagus | ESCC | 2.17e-04 | 1.53e+00 | 0.0655 |
| 9021 | SOCS3 | LZE6T | Human | Esophagus | ESCC | 2.87e-04 | -3.98e-01 | 0.0845 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004343424 | Oral cavity | EOLP | response to peptide hormone | 89/2218 | 414/18723 | 1.29e-08 | 6.11e-07 | 89 |
| GO:003286922 | Oral cavity | EOLP | cellular response to insulin stimulus | 53/2218 | 203/18723 | 1.65e-08 | 7.43e-07 | 53 |
| GO:007137523 | Oral cavity | EOLP | cellular response to peptide hormone stimulus | 68/2218 | 290/18723 | 1.98e-08 | 8.62e-07 | 68 |
| GO:003286823 | Oral cavity | EOLP | response to insulin | 62/2218 | 264/18723 | 7.78e-08 | 2.76e-06 | 62 |
| GO:000189023 | Oral cavity | EOLP | placenta development | 39/2218 | 144/18723 | 4.49e-07 | 1.25e-05 | 39 |
| GO:000189222 | Oral cavity | EOLP | embryonic placenta development | 26/2218 | 82/18723 | 1.50e-06 | 3.55e-05 | 26 |
| GO:000828615 | Oral cavity | EOLP | insulin receptor signaling pathway | 32/2218 | 116/18723 | 3.06e-06 | 6.70e-05 | 32 |
| GO:000170123 | Oral cavity | EOLP | in utero embryonic development | 72/2218 | 367/18723 | 1.02e-05 | 1.83e-04 | 72 |
| GO:006145824 | Oral cavity | EOLP | reproductive system development | 81/2218 | 427/18723 | 1.09e-05 | 1.93e-04 | 81 |
| GO:004662612 | Oral cavity | EOLP | regulation of insulin receptor signaling pathway | 21/2218 | 66/18723 | 1.41e-05 | 2.36e-04 | 21 |
| GO:004860823 | Oral cavity | EOLP | reproductive structure development | 80/2218 | 424/18723 | 1.51e-05 | 2.50e-04 | 80 |
| GO:199082315 | Oral cavity | EOLP | response to leukemia inhibitory factor | 26/2218 | 95/18723 | 2.91e-05 | 4.20e-04 | 26 |
| GO:00507321 | Oral cavity | EOLP | negative regulation of peptidyl-tyrosine phosphorylation | 19/2218 | 59/18723 | 2.95e-05 | 4.24e-04 | 19 |
| GO:190007611 | Oral cavity | EOLP | regulation of cellular response to insulin stimulus | 20/2218 | 64/18723 | 3.01e-05 | 4.30e-04 | 20 |
| GO:00313482 | Oral cavity | EOLP | negative regulation of defense response | 53/2218 | 258/18723 | 4.05e-05 | 5.54e-04 | 53 |
| GO:006070612 | Oral cavity | EOLP | cell differentiation involved in embryonic placenta development | 11/2218 | 25/18723 | 5.72e-05 | 7.26e-04 | 11 |
| GO:199083014 | Oral cavity | EOLP | cellular response to leukemia inhibitory factor | 25/2218 | 94/18723 | 6.89e-05 | 8.53e-04 | 25 |
| GO:00321023 | Oral cavity | EOLP | negative regulation of response to external stimulus | 75/2218 | 420/18723 | 1.74e-04 | 1.80e-03 | 75 |
| GO:0043550 | Oral cavity | EOLP | regulation of lipid kinase activity | 19/2218 | 71/18723 | 4.53e-04 | 3.99e-03 | 19 |
| GO:00182121 | Oral cavity | EOLP | peptidyl-tyrosine modification | 65/2218 | 378/18723 | 1.25e-03 | 9.02e-03 | 65 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0493220 | Endometrium | AEH | Non-alcoholic fatty liver disease | 67/1197 | 155/8465 | 5.91e-19 | 1.75e-17 | 1.28e-17 | 67 |
| hsa0412016 | Endometrium | AEH | Ubiquitin mediated proteolysis | 41/1197 | 142/8465 | 3.42e-06 | 4.27e-05 | 3.13e-05 | 41 |
| hsa04932110 | Endometrium | AEH | Non-alcoholic fatty liver disease | 67/1197 | 155/8465 | 5.91e-19 | 1.75e-17 | 1.28e-17 | 67 |
| hsa0412017 | Endometrium | AEH | Ubiquitin mediated proteolysis | 41/1197 | 142/8465 | 3.42e-06 | 4.27e-05 | 3.13e-05 | 41 |
| hsa0493225 | Endometrium | EEC | Non-alcoholic fatty liver disease | 67/1237 | 155/8465 | 3.53e-18 | 1.06e-16 | 7.87e-17 | 67 |
| hsa0412023 | Endometrium | EEC | Ubiquitin mediated proteolysis | 41/1237 | 142/8465 | 7.86e-06 | 9.58e-05 | 7.14e-05 | 41 |
| hsa046687 | Endometrium | EEC | TNF signaling pathway | 27/1237 | 114/8465 | 6.47e-03 | 3.22e-02 | 2.40e-02 | 27 |
| hsa0493235 | Endometrium | EEC | Non-alcoholic fatty liver disease | 67/1237 | 155/8465 | 3.53e-18 | 1.06e-16 | 7.87e-17 | 67 |
| hsa0412033 | Endometrium | EEC | Ubiquitin mediated proteolysis | 41/1237 | 142/8465 | 7.86e-06 | 9.58e-05 | 7.14e-05 | 41 |
| hsa0466814 | Endometrium | EEC | TNF signaling pathway | 27/1237 | 114/8465 | 6.47e-03 | 3.22e-02 | 2.40e-02 | 27 |
| hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
| hsa04932210 | Esophagus | ESCC | Non-alcoholic fatty liver disease | 122/4205 | 155/8465 | 5.69e-14 | 1.59e-12 | 8.14e-13 | 122 |
| hsa0466810 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
| hsa0516425 | Esophagus | ESCC | Influenza A | 122/4205 | 171/8465 | 5.01e-09 | 4.79e-08 | 2.45e-08 | 122 |
| hsa051609 | Esophagus | ESCC | Hepatitis C | 107/4205 | 157/8465 | 1.75e-06 | 1.08e-05 | 5.55e-06 | 107 |
| hsa049109 | Esophagus | ESCC | Insulin signaling pathway | 89/4205 | 137/8465 | 1.97e-04 | 7.32e-04 | 3.75e-04 | 89 |
| hsa049318 | Esophagus | ESCC | Insulin resistance | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
| hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
| hsa0493238 | Esophagus | ESCC | Non-alcoholic fatty liver disease | 122/4205 | 155/8465 | 5.69e-14 | 1.59e-12 | 8.14e-13 | 122 |
| hsa0466817 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
| Page: 1 2 3 4 5 6 7 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SOCS3 | SNV | Missense_Mutation | rs866275313 | c.385N>T | p.Pro129Ser | p.P129S | O14543 | protein_coding | tolerated(0.35) | benign(0.007) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SOCS3 | SNV | Missense_Mutation | novel | c.22N>A | p.Pro8Thr | p.P8T | O14543 | protein_coding | tolerated(0.17) | benign(0.045) | TCGA-VS-A9V1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| SOCS3 | deletion | Frame_Shift_Del | novel | c.347_354delNNNNNNNN | p.Arg116LeufsTer24 | p.R116Lfs*24 | O14543 | protein_coding | TCGA-C5-A7UH-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | ||
| SOCS3 | insertion | Frame_Shift_Ins | novel | c.299dupG | p.Ser101GlnfsTer42 | p.S101Qfs*42 | O14543 | protein_coding | TCGA-EA-A43B-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | ||
| SOCS3 | SNV | Missense_Mutation | c.160N>A | p.Gly54Ser | p.G54S | O14543 | protein_coding | tolerated(0.44) | benign(0.055) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| SOCS3 | SNV | Missense_Mutation | c.281N>A | p.Arg94His | p.R94H | O14543 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
| SOCS3 | SNV | Missense_Mutation | c.82A>C | p.Lys28Gln | p.K28Q | O14543 | protein_coding | tolerated(0.15) | benign(0.312) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| SOCS3 | SNV | Missense_Mutation | rs780147259 | c.589N>A | p.Val197Ile | p.V197I | O14543 | protein_coding | tolerated(0.2) | possibly_damaging(0.739) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| SOCS3 | deletion | Frame_Shift_Del | c.299delG | p.Gly100AlafsTer79 | p.G100Afs*79 | O14543 | protein_coding | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |||
| SOCS3 | deletion | Frame_Shift_Del | c.299delN | p.Gly100AlafsTer79 | p.G100Afs*79 | O14543 | protein_coding | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 9021 | SOCS3 | KINASE, CLINICALLY ACTIONABLE | ANTISENSE OLIGONUCLEOTIDES | 15939448 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |